These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 15573872)

  • 1. SCIO-469 Scios Inc.
    Nikas SN; Drosos AA
    Curr Opin Investig Drugs; 2004 Nov; 5(11):1205-12. PubMed ID: 15573872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p38 MAP kinase inhibitors: many are made, but few are chosen.
    Dominguez C; Powers DA; Tamayo N
    Curr Opin Drug Discov Devel; 2005 Jul; 8(4):421-30. PubMed ID: 16022178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug evaluation: VX-702, a MAP kinase inhibitor for rheumatoid arthritis and acute coronary syndrome.
    Ding C
    Curr Opin Investig Drugs; 2006 Nov; 7(11):1020-5. PubMed ID: 17117592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective p38alpha inhibitors clinically evaluated for the treatment of chronic inflammatory disorders.
    Goldstein DM; Kuglstatter A; Lou Y; Soth MJ
    J Med Chem; 2010 Mar; 53(6):2345-53. PubMed ID: 19950901
    [No Abstract]   [Full Text] [Related]  

  • 5. Inhibitors of p38 mitogen-activated protein kinase for the treatment of rheumatoid arthritis.
    Pargellis C; Regan J
    Curr Opin Investig Drugs; 2003 May; 4(5):566-71. PubMed ID: 12833650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigations of SCIO-469-like compounds for the inhibition of p38 MAP kinase.
    Laufer S; Lehmann F
    Bioorg Med Chem Lett; 2009 Mar; 19(5):1461-4. PubMed ID: 19195885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of a p38 mitogen activated protein kinase inhibitor in mitigating an established inflammatory reaction to polyethylene particles in vivo.
    Ma T; Ren PG; Larsen DM; Suenaga E; Zilber S; Genovese M; Smith RL; Goodman SB
    J Biomed Mater Res A; 2009 Apr; 89(1):117-23. PubMed ID: 18431764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A 24-week, randomized, double-blind, placebo-controlled, parallel group study of the efficacy of oral SCIO-469, a p38 mitogen-activated protein kinase inhibitor, in patients with active rheumatoid arthritis.
    Genovese MC; Cohen SB; Wofsy D; Weinblatt ME; Firestein GS; Brahn E; Strand V; Baker DG; Tong SE
    J Rheumatol; 2011 May; 38(5):846-54. PubMed ID: 21285160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-inflammatory properties of a novel N-phenyl pyridinone inhibitor of p38 mitogen-activated protein kinase: preclinical-to-clinical translation.
    Hope HR; Anderson GD; Burnette BL; Compton RP; Devraj RV; Hirsch JL; Keith RH; Li X; Mbalaviele G; Messing DM; Saabye MJ; Schindler JF; Selness SR; Stillwell LI; Webb EG; Zhang J; Monahan JB
    J Pharmacol Exp Ther; 2009 Dec; 331(3):882-95. PubMed ID: 19720877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Edotecarin.
    Denny WA
    IDrugs; 2004 Feb; 7(2):173-7. PubMed ID: 15057663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kinases as targets: prospects for chronic therapy.
    Orchard S
    Curr Opin Drug Discov Devel; 2002 Sep; 5(5):713-7. PubMed ID: 12630291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SAR of benzoylpyridines and benzophenones as p38alpha MAP kinase inhibitors with oral activity.
    Revesz L; Blum E; Di Padova FE; Buhl T; Feifel R; Gram H; Hiestand P; Manning U; Rucklin G
    Bioorg Med Chem Lett; 2004 Jul; 14(13):3601-5. PubMed ID: 15177483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel series of p38 MAP kinase inhibitors for the potential treatment of rheumatoid arthritis.
    Brown DS; Belfield AJ; Brown GR; Campbell D; Foubister A; Masters DJ; Pike KG; Snelson WL; Wells SL
    Bioorg Med Chem Lett; 2004 Nov; 14(21):5383-7. PubMed ID: 15454231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological properties of SD-282 - an alpha-isoform selective inhibitor for p38 MAP kinase.
    Koppelman B; Webb HK; Medicherla S; Almirez R; Feng Y; Chavez JC; Mao CP; Nguyen A; Liu YW; Kapoun AM; Muiru G; Huang YA; Dugar S; Mavunkel BJ; Lim DW; Chakravarty S; Luedtke G; Protter AA; Higgins LS
    Pharmacology; 2008; 81(3):204-20. PubMed ID: 18176091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibitors of unactivated p38 MAP kinase.
    Bullington J; Argentieri D; Averill K; Carter D; Cavender D; Fahmy B; Fan X; Hall D; Heintzelman G; Jackson P; Leung WP; Li X; Ling P; Olini G; Razler T; Reuman M; Rupert K; Russell R; Siekierka J; Wadsworth S; Wolff R; Xiang B; Zhang YM
    Bioorg Med Chem Lett; 2006 Dec; 16(23):6102-6. PubMed ID: 16971122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and synthesis of potent pyridazine inhibitors of p38 MAP kinase.
    Tamayo N; Liao L; Goldberg M; Powers D; Tudor YY; Yu V; Wong LM; Henkle B; Middleton S; Syed R; Harvey T; Jang G; Hungate R; Dominguez C
    Bioorg Med Chem Lett; 2005 May; 15(9):2409-13. PubMed ID: 15837335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BMS-582949: crystalline form of a p38alpha inhibitor? WO2008079857.
    Norman P
    Expert Opin Ther Pat; 2009 Aug; 19(8):1165-8. PubMed ID: 19505194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kinase inhibitors: a new approach to rheumatoid arthritis treatment.
    Cohen S; Fleischmann R
    Curr Opin Rheumatol; 2010 May; 22(3):330-5. PubMed ID: 20164774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of p38 mitogen-activated protein kinase in ozone-induced airway hyperresponsiveness and inflammation.
    Williams AS; Issa R; Durham A; Leung SY; Kapoun A; Medicherla S; Higgins LS; Adcock IM; Chung KF
    Eur J Pharmacol; 2008 Dec; 600(1-3):117-22. PubMed ID: 18926814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential of p38-MAPK inhibitors in the treatment of ischaemic heart disease.
    Clark JE; Sarafraz N; Marber MS
    Pharmacol Ther; 2007 Nov; 116(2):192-206. PubMed ID: 17765316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.